Overall survival (OS) in EBV-positive (study group) and EBV-negative (control group) elderly DLBCL patients in a matched case-control analysis.

<p>Overall survival (OS) in EBV-positive (study group) and EBV-negative (control group) elderly DLBCL patients in a matched case-control analysis.</p

Clinical features and survival outcomes of 16 EBV-positive elderly DLBCL patients.

<p>M, male; F, female; LN, lymph node; IPI, International Prognostic Index; R, Rituximab; CHOP, cyclophosphamide, doxorubicin(may be substituted by epirubicin or peglyated liposome doxorubicin), vincristine,prednisone; EPOCH, etoposide, cyclophosphamide, doxorubicin, vincristine, prednisone; CR, complete remission; PR, partial remission; SD, stable disease; PD, progressive disease; AWD, alive with disease; AND, alive with no evidence of disease; DOD, died of disease.</p><p>Clinical features and survival outcomes of 16 EBV-positive elderly DLBCL patients.</p

Treatment responses and survival outcomes of EBV-positive (study group) and EBV-negative (control group) elderly DLBCL patients.

<p>CR, complete remission; PFS, progression free survival; OS, overall survival.</p><p>Treatment responses and survival outcomes of EBV-positive (study group) and EBV-negative (control group) elderly DLBCL patients.</p